Treatment of bleeding in hemophilia

	Hemophilia A	Hemophilia B
Major/severe bleeding* Raise factor level to 80 to 100%	Factor VIII dose of approximately 50 units/kg	Factor IX dose of approximately 100 to 120 units/kg
Hemarthrosis Raise factor level to 40 to 50%	Factor VIII dose of approximately 25 units/kg	Factor IX dose of approximately 50 to 60 units/kg

This table is a general guide and does not replace clinical judgment in determining the severity of bleeding, risk of morbidity, factor dosing, and need for other treatments. Mucosal bleeding can be treated with antifibrinolytics or local hemostatic therapies concomitantly with factor infusion. Patients with mild hemophilia A and minor bleeding may be treated with DDAVP if they have previously demonstrated a response. Patients with inhibitors may require a bypassing agent such as recombinant activated factor VII (rFVIIa) or FEIBA. Do not use antifibrinolytics with FEIBA concomitantly. Refer to UpToDate for additional information about management of bleeding in patients with hemophilia.

FEIBA: Factor eight inhibitor bypassing agent.
* Examples of major bleeding include bleeding affecting the central nervous system, airway, hip, deep muscle with neurovascular injury, or abdomen; bleeding that cannot be controlled with local therapies, or bleeding necessitating transfusion.

Graphic 110820 Version 1.0

خرید پکیج

Treatment of bleeding in hemophilia